Cai Z, Tian X and Dong L
Nivolumab is an immune checkpoint inhibitor used to treat various advanced malignancies including metastatic non-small cell lung cancer. The side effects of immunotest inhibitors are different from traditional cytotoxic chemotherapy and pericardial effusion is one of the adverse effects of immunotherapy. However, here we present a 59-year-old male with advanced non-small cell lung cancer (NSCLC) treated with nivolumab who successfully managed reduction of pericardial effusion in patients treated by Nivolumab after 11 cycles. During the treatment, he underwent only one pericardial puncture and drainage of pericardial effusion.
इस लेख का हिस्सा
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Telugu 